Glaukos
Glaukos Corp is an American ophthalmic medical technology company developing therapies for glaucoma, corneal disorders, and retinal diseases. The company designs, manufactures, and commercializes micro-invasive glaucoma surgery devices, sustained-release pharmaceutical implants, and corneal cross-linking systems. Main revenue drivers consist of sales of the iStent family of micro-bypass stents, iDose sustained-release implants, and Photrexa corneal formulations. Glaukos serves ophthalmic surgeons, eye care clinics, ambulatory surgical centers, and outpatient hospitals across North America, Europe, and Asia-Pacific. The company holds a pioneer position as the creator and market leader of the micro-invasive glaucoma surgery segment. Headquartered in Aliso Viejo, California, Glaukos Corp is listed on the New York Stock Exchange.
5 of the funds FundTelligence covers report a position in Glaukos.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
- Exposure themes
- Ageing & Longevity, Healthy Ageing & Function, Vision
Funds holding Glaukos
- C WorldWide Healthcare Select — C WorldWide · 5.0 % (largest positions only, October 2026)
- JPM US Small Cap Growth Fund — JPM · 0.44 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.14 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.09 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.07 % (partially disclosed portfolio, June 2026)